SCHEMBL2123592

SCHEMBL2123592

Cc1c(N2CCOCC2)ccc2c1NCC2(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PIK3CA P42336 6/20 0.37
▸ LMNA P02545 3/20 0.35
▸ NSD2 O96028 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ LGMN Q99538 1/20 0.35
▸ PIK3CD O00329 4/20 0.34
▸ PIK3CB P42338 4/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2125523 0.76 L3MBTL1 (0.40) MAPTALDH1A1L3MBTL1GAAMEN1
SCHEMBL30168889 0.73 LGMN (0.53) MAPTALDH1A1L3MBTL1GAAMEN1
SCHEMBL546488 0.73 LGMN (0.53) MAPTALDH1A1L3MBTL1GAAMEN1
SCHEMBL1199030 0.70 L3MBTL1 (0.51) MAPTALDH1A1L3MBTL1GAAMEN1
SCHEMBL2124038 0.70 LGMN (0.45) MAPTALDH1A1MEN1KMT2APIK3CA
SCHEMBL2608562 0.69 GAA (0.40) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL24196221 0.65 MAPT (0.46) MAPTALDH1A1L3MBTL1GAAMEN1
SCHEMBL21893900 0.63 ADRB1 (0.62) MAPTALDH1A1GAAMEN1KMT2A
SCHEMBL19474576 0.63 ALDH1A1 (0.54) MAPTALDH1A1MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL10887133 0.63 PIK3CA (0.48) MAPTALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 — — US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 — — US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 — — US disclosed
EP-2445902-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY Amgen, Inc (US) 2012-05-02 — — EP disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 — — US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 — — US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 — — US disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 — — WO disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 MAPT 3420/4885ALDH1A1 3735/4885L3MBTL1 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback